Novartis is expecting strong sales and profits from Lucentis, a very expensive new drug intended to treat age-related wet macular degeneration, that has already been introduced in the USA by its developer Genentech, which has given to the Swiss firm the rights for the rest of the world
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.